CRL · News · 20260805N
Revenue Performance and Mix
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 31 · Surprise 32 · No source text
Charles River reported Q2 2026 revenue of approximately $1.00 billion, down 2.7% year over year. Discovery and Safety Assessment benefited from recovering demand, while Resources Management Services faced headwinds. Manufacturing delivered strong performance, aided by portfolio changes and divestitures. Demand improved among small and midsized biotech customers and global biopharma clients.
Key facts
- Q2 2026 GAAP revenue: $1.00 billion, a 2.7% decrease year-over-year. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | realized | -2.7% | Q2 2026 GAAP revenue: $1.00 billion, a 2.7% decrease year-over-year. |